Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
boston top stories
givosiran
3
×
life sciences
national blog main
acute hepatic porphyria
aminolevulinic acid
boston
clinical trials
drugs
rna interference
2019
accelerated approval
activism
acute hepatic porphyrias
akin akinc
bernie sanders
biotech
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
buyout
celgene
charges
congress
crisis
detroit blog main
detroit top stories
drug prices
easl
fatty liver disease
fda
house of representatives
indiana blog main
indiana top stories
indivior
insulin
intercept pharmaceuticals
lawsuit
What
drug
3
×
alnylam
approval
interference
medicine
pharmaceuticals
rna
rnai
second
seek
speedy
advanced
ago
alnylam’s
bff
bio
cleared
conference
data
deals
devoted
disease
easl
far
fda
form
gene
indicated
kicked
liver
major
market
nasdaq
new
nod
ok
quick
race
roundup
therapy
Language
Current search:
givosiran
×
drug
×
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
